Target
Tyrosine-protein kinase Lck
Ligand
BDBM50194699
Substrate
n/a
Meas. Tech.
ChEMBL_396621 (CHEMBL913225)
IC50
200±n/a nM
Citation
 DiMauro, EFNewcomb, JNunes, JJBemis, JEBoucher, CBuchanan, JLBuckner, WHCee, VJChai, LDeak, HLEpstein, LFFaust, TGallant, PGeuns-Meyer, SDGore, AGu, YHenkle, BHodous, BLHsieh, FHuang, XKim, JLLee, JHMartin, MWMasse, CEMcGowan, DCMetz, DMohn, DMorgenstern, KAOliveira-dos-Santos, APatel, VFPowers, DRose, PESchneider, STomlinson, SATudor, YYTurci, SMWelcher, AAWhite, RDZhao, HZhu, LZhu, X Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity. J Med Chem 49:5671-86 (2006) [PubMed]  Article 
Target
Name:
Tyrosine-protein kinase Lck
Synonyms:
2.7.10.2 | LCK | LCK_HUMAN | LSK | Leukocyte C-terminal Src kinase | Lymphocyte cell-specific protein-tyrosine kinase | Lymphocyte-specific protein tyrosine kinase | P56-LCK | Protein YT16 | Proto-oncogene Lck | Proto-oncogene tyrosine-protein kinase LCK | Src/Lck kinase | T cell-specific protein-tyrosine kinase
Type:
n/a
Mol. Mass.:
57987.83
Organism:
Homo sapiens (Human)
Description:
P06239
Residue:
509
Sequence:
MGCGCSSHPEDDWMENIDVCENCHYPIVPLDGKGTLLIRNGSEVRDPLVTYEGSNPPASPLQDNLVIALHSYEPSHDGDLGFEKGEQLRILEQSGEWWKAQSLTTGQEGFIPFNFVAKANSLEPEPWFFKNLSRKDAERQLLAPGNTHGSFLIRESESTAGSFSLSVRDFDQNQGEVVKHYKIRNLDNGGFYISPRITFPGLHELVRHYTNASDGLCTRLSRPCQTQKPQKPWWEDEWEVPRETLKLVERLGAGQFGEVWMGYYNGHTKVAVKSLKQGSMSPDAFLAEANLMKQLQHQRLVRLYAVVTQEPIYIITEYMENGSLVDFLKTPSGIKLTINKLLDMAAQIAEGMAFIEERNYIHRDLRAANILVSDTLSCKIADFGLARLIEDNEYTAREGAKFPIKWTAPEAINYGTFTIKSDVWSFGILLTEIVTHGRIPYPGMTNPEVIQNLERGYRMVRPDNCPEELYQLMRLCWKERPEDRPTFDYLRSVLEDFFTATEGQYQPQP
  
Inhibitor
Name:
BDBM50194699
Synonyms:
3-(2-aminoquinazolin-6-yl)-2-methyl-N-(3-(trifluoromethyl)phenyl)benzamide | CHEMBL215892
Type:
Small organic molecule
Emp. Form.:
C23H17F3N4O
Mol. Mass.:
422.4025
SMILES:
Cc1c(cccc1-c1ccc2nc(N)ncc2c1)C(=O)Nc1cccc(c1)C(F)(F)F
Structure:
Search PDB for entries with ligand similarity: